Vir Biotechnology, Inc.

NASDAQ:VIR

Biotechnology

Healthcare
$9.15 -2.63%

-$0.25 today

Market cap
$1.57B
Beta
1.64
P/E (TTM)
-3.0
EPS (TTM)
-$3.00
52W Low $4.16High $11.66

Volume 2.15M

Average 1.76M

VIR Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Vir Biotechnology, Inc.NASDAQ: VIR

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash declines year over year

Q1 FY2026 net change in cash of $41.98M fell 14.8% year over year, ahead of the -145.3% change in trailing-twelve-month net change in cash. Sequentially, it fell 32.1% from the prior quarter.

Context

  • Net change in cash amounted to 113.2% of revenue in FY2025, up 35.9 pp from a year earlier.
  • Net change in cash increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -14.8% holds above the trailing-twelve-month pace of -145.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$41.98M-32.1% QoQ
Last fiscal yearDec 2025
-$77.63M-235.2% YoY
LTMMar 2026
-$84.95M-145.3% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-14.8%——
1 year-235.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
(77.63M) USD
Year-over-year change
-235.2%

Net Change in Cash vs competitors

How VIR compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -145.3% is the 8th highest of 10, against a peer median of +65.2%.
  • Net change in cash amounts to 129.7% of revenue for VIR, versus a peer median of 9.2%.
VIR Competitors
Net Change in Cash for VIR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€774.56M EUR-183.0%—29.3%
VIRVir Biotechnology, Inc.LTM Mar 2026$84.95M USD-145.3%—129.7%
MRNAModerna, Inc.LTM Sep 2026$61M USD+111.9%—2.4%
VALNValneva SELTM Mar 2026€53.7M EUR+127.1%+0.8%34.4%
NVAXNovavax, Inc.LTM Mar 2026$45.6M USD-79.0%+17.3%7.6%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$40.08M USD-3.5%——
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$25.29M USD+542.2%-17.4%36.5%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$21.41M USD-320.3%-20.0%2.3%
ABUSArbutus Biopharma CorporationLTM Mar 2026$13.37M USD+121.9%-38.4%7.0%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$7.71M USD+65.2%+43.6%10.8%
Peer median (excluding VIR) —+65.2%-8.3%9.2%

Competitors are the stored peer set for VIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income528.58M515.84M(615.06M)(521.96M)(437.99M)
Depreciation & Amortization5.81M6.78M19.45M14.56M21.15M
Deferred Income Tax15.19M(15.19M)(1.06M)(2.95M)0
Stock-Based Compensation83.78M102.08M078.46M49.07M
Change in Working Capital(628.39M)665.37M(304.59M)(84.01M)(22.45M)
Accounts Receivables(773.08M)770.04M(565K)(6.51M)0
Inventory52.82M0000
Accounts Payables(171K)797K732K(988K)5M
Other Working Capital92.04M(105.47M)(304.76M)(76.51M)(27.44M)
Other Non-Cash Items(52.56M)388.37M122.48M69.55M(1.57M)
Operating Cash Flow(47.59M)1.66B(778.79M)(446.35M)(391.78M)
Capital Expenditures(21.82M)(68.01M)(21.57M)(7.3M)(4.83M)
Acquisitions (Net)140.81M0100K3.37M253K
Purchases of Investments(420.24M)(1.48B)(2.02B)(1.24B)(886.33M)
Sales of Investments301.24M351.51M2.2B1.74B1.2B
Other Investing Activities(140.81M)0000
Investing Cash Flow(140.81M)(1.19B)164.73M499.37M310.37M
Debt Repayment(259K)(260K)(287K)(165K)(361K)
Common Stock Issued85.21M28.46M7.77M4.55M4.15M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities15.38M6.56M(100K)00
Financing Cash Flow100.33M34.76M7.38M4.39M3.79M
Effect of Forex Changes00208K00
Net Change in Cash(88.07M)504.55M(606.47M)57.4M(77.63M)
Free Cash Flow(69.41M)1.6B(800.36M)(453.65M)(396.61M)

Vir Biotechnology, Inc.

NASDAQ:VIR

Intrinsic Alpha fair value

Locked

Current Price

$9.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.